Ascendiant Capital Markets set a $1.00 target price on Hemispherx BioPharma (NYSEAMERICAN:HEB) in a report released on Friday morning, TipRanks reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Hemispherx BioPharma stock traded down $0.01 during mid-day trading on Friday, reaching $0.14. The stock had a trading volume of 3,137,296 shares, compared to its average volume of 2,607,680. Hemispherx BioPharma has a fifty-two week low of $0.13 and a fifty-two week high of $0.35.

Hemispherx BioPharma (NYSEAMERICAN:HEB) last announced its quarterly earnings data on Monday, April 1st. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.04. The firm had revenue of $0.24 million during the quarter.

About Hemispherx BioPharma

Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).

Further Reading: Percentage Gainers

Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with's FREE daily email newsletter.